Improving imaging techniques for Moyamoya Disease
IMAGINE - Imaging in Moyamoya Disease
This study is testing new imaging techniques to see if they can improve care for people with Moyamoya Disease by better understanding how blood flow changes over time.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | University Hospital Tuebingen Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Tübingen, Baden-Wurttemberg) |
| Trial ID | NCT06330818 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance patient care for individuals with Moyamoya Disease by investigating various imaging technologies to better understand cerebral hemodynamics and disease progression. It involves analyzing CO2-triggered BOLD fMRI in comparison to H2 15O PET/CT, as well as examining longitudinal changes in vessel-wall imaging and correlating these with biosampling. The goal is to establish standardized imaging recommendations for pre- and postoperative assessments in Moyamoya patients.
Who should consider this trial
Good fit: Ideal candidates include patients suspected of having Moyamoya Disease who can provide informed consent.
Not a fit: Patients with cerebral vascular disease due to atherosclerosis, vasculitis, or those with contraindications to MRI or PET/CT will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and treatment strategies for Moyamoya Disease, potentially reducing the risk of strokes.
How similar studies have performed: While there have been studies on imaging techniques in cerebrovascular diseases, this specific approach in Moyamoya Disease is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with suspicion of Moyamoya Disease * Patients able to understand the study and to give their informed consent Exclusion Criteria: * Cerebral vascular disease caused by atherosclerosis * Vasculitis * Contraindications to MRI * Contraindications to PET/CT * Pregnancy * Inability to give informed consent * Renal insufficiency
Where this trial is running
Tübingen, Baden-Wurttemberg
- University of Tuebingen, Neurosurgery — Tübingen, Baden-Wurttemberg, Germany (Recruiting)
Study contacts
- Study coordinator: Constantin Roder, Prof. Dr., MD
- Email: constantin.roder@med.uni-tuebingen.de
- Phone: 0049-7071290
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.